Cellular Origins, a company focused on enabling scalable and efficient manufacture of cell and gene therapies (CGTs), has announced a collaborative partnership with ScaleReady, a joint venture between Bio-Techne, Fresenius Kabi and Wilson Wolf that brings together process development expertise, tools and technologies for scalable CGT manufacturing.
The partnership aims to automate portions of ScaleReady’s CGT manufacturing workflow by using Cellular Origin’s robotic system for sterile liquid transfer.
Cellular Origins’ and ScaleReady’s first project will be to standardise and automate interconnections between the modules of ScaleReady’s G-Rex(R), a manufacturing platform used by therapy developers internationally to produce CGTs for clinical trials, including the most recently approved commercial therapies. This integration of Cellular Origins’ robotic system will eliminate variability in manual connection techniques. Further projects will automate additional components of ScaleReady’s workflow, such as the robotic movement of G-Rex into and out of incubators.
